Crossmark

Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy

Crossref DOI link: https://doi.org/10.1016/j.clinsp.2023.100177

Published Print: 2023-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Gutic, Bojana http://orcid.org/0000-0002-5959-6772
Bozanovic, Tatjana http://orcid.org/0000-0001-5089-715X
Mandic, Aljosa http://orcid.org/0000-0002-6719-8694
Dugalic, Stefan http://orcid.org/0000-0001-5292-0595
Todorovic, Jovana http://orcid.org/0000-0001-9741-6317
Stanisavljevic, Dejana http://orcid.org/0000-0001-8899-2929
Dugalic, Miroslava Gojnic http://orcid.org/0000-0002-7926-3916
Sengul, Demet http://orcid.org/0000-0002-0416-0621
Detanac, Dzenana A. http://orcid.org/0000-0001-9225-6879
Sengul, Ilker http://orcid.org/0000-0001-5217-0755
Detanac, Dzemail http://orcid.org/0000-0002-4823-5867
Soares, José Maria Junior http://orcid.org/0000-0003-0774-9404
Funding

Funding for this research was provided by:

FAPESP
License Information

Text and Data Mining valid from 2023-01-01

Text and Data Mining valid from 2023-01-01

Version of Record valid from 2023-02-20
More Information

This article is maintained by: Elsevier

Article Title: Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy

Journal Title: Clinics

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.clinsp.2023.100177

Content Type: article

Copyright: © 2023 HCFMUSP. Published by Elsevier España, S.L.U.